Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.

about

Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.

Item

http://www.wikidata.org/entity/Q47368780

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Forty years of landmark trials ...... n international collaboration.

@en

Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group

@nl

type

Item

label

Forty years of landmark trials ...... n international collaboration.

@en

Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group

@nl

prefLabel

Forty years of landmark trials ...... n international collaboration.

@en

Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group

@nl

P1476

Forty years of landmark trials ...... in international collaboration

@en

P2093

Bent Ejlertsen

http://www.w3.org/2001/XMLSchema#string

Birgitte Vrou Offersen

http://www.w3.org/2001/XMLSchema#string

Henning Mouridsen

http://www.w3.org/2001/XMLSchema#string

Jens Overgaard

http://www.w3.org/2001/XMLSchema#string

Maj-Britt Jensen

http://www.w3.org/2001/XMLSchema#string

Peer Christiansen

http://www.w3.org/2001/XMLSchema#string

P2860

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005.

Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

P304

3-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/0284186X.2017.1408962

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ann Knoop

Niels Kroman

P577

2017-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29205077

http://www.w3.org/2001/XMLSchema#string

P921

collaboration